I
1.55
-0.24 (-13.41%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Indaptus Therapeutics, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
0.4
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.38 |
|
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 36.87% |
| 机构持股比例 | 13.08% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 29 Dec 2025 | 公告 | Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合